GALAFOLD Drug Patent Profile

When do Galafold patents expire, and when can generic versions of Galafold launch?

Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are sixty-six patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and sixty-nine patent family members in thirty-two countries.

The generic ingredient in GALAFOLD is migalastat hydrochloride. One supplier is listed for this compound. Additional details are available on the migalastat hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Galafold

Galafold was eligible for patent challenges on August 10, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 16, 2039. This may change due to patent challenges or generic licensing.

There have been fifteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GALAFOLD

International Patents:	369
US Patents:	66
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	10
Patent Applications:	368
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GALAFOLD
What excipients (inactive ingredients) are in GALAFOLD?	GALAFOLD excipients list
DailyMed Link:	GALAFOLD at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GALAFOLD

NDA:

208623

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GALAFOLD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amicus Therapeutics	Phase 3
Amicus Therapeutics	Phase 2

See all GALAFOLD clinical trials

Paragraph IV (Patent) Challenges for GALAFOLD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GALAFOLD	Capsules	migalastat hydrochloride	123 mg	208623	3	2022-08-10

US Patents and Regulatory Information for GALAFOLD

GALAFOLD is protected by sixty-seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes				Y
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes

International Patents for GALAFOLD

When does loss-of-exclusivity occur for GALAFOLD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GALAFOLD around the world.

Country	Patent Number	Title	Estimated Expiration
China	109069494
China	114159436
European Patent Office	3432882
Japan	2019510030
Japan	2022130589

Supplementary Protection Certificates for GALAFOLD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2787345	300843	Netherlands		PRODUCT NAME: MIGALASTAT OF EEN ZOUT DAARVAN, WAARONDER HET HYDROCHLORIDEZOUT; REGISTRATION NO/DATE: EU/1/15/1082 20160531
2787345	PA2016033	Lithuania		PRODUCT NAME: MIGALASTATAS ARBA JO DRUSKA, ISKAITANT IR HIDROCHLORIDO DRUSKA; REGISTRATION NO/DATE: EU/1/15/1082 20160526
2787345	122016000090	Germany		PRODUCT NAME: MIGALASTAT ODER EIN SALZ DAVON, EINSCHLIESSLICH DES HYDROCHLORIDSALZES; REGISTRATION NO/DATE: EU/1/15/1082/001 20160526
2787345	CA 2016 00055	Denmark		PRODUCT NAME: MIGALASTAT ELLER ET SALT HERAF, HERUNDER HYDROGENKLORIDSALTET; REG. NO/DATE: EU/1/15/1082 20160531
2787345	93312	Luxembourg		PRODUCT NAME: MIGALASTAT OU UN SEL DE CELUI-CI , Y COMPRIS LE SEL DE CHLORHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1082 - GALAFOLD - MIGALASTAT

GALAFOLD (migalastat) Market Dynamics and Financial Trajectory: Exclusivity, Pricing Power, Revenue Exposure, and Generic/Biosimilar Risk

Last updated: July 23, 2026

GALAFOLD (migalastat) is a precision medicine for Fabry disease with amenable GLA mutations. Market growth depends on diagnosis rates, testing for “amenable” mutations, payer coverage decisions, and persistence in specialized care settings. Financial trajectory is shaped by patent/exclusivity duration, loss of exclusivity timing, and pricing pressure from higher-penetration competitors in Fabry disease (enzyme replacement therapies and supportive-choice switching). In the near term, the biggest demand driver is the share of diagnosed patients whose mutations are confirmed as migalastat-amenable; the biggest value risk is payer re-contracting and formulary steering as competitive alternatives expand.

What is the commercial positioning of GALAFOLD (migalastat) in Fabry disease?

GALAFOLD is an oral therapy taken every other day for Fabry patients with certain “amenable” mutations. Its commercial proposition is convenience versus intravenous enzyme replacement therapy (ERT) and the clinical goal of stabilizing disease parameters in eligible patients.

What patient segments buy GALAFOLD first?

Payers and provider channels typically concentrate initial uptake among:

• Patients already under Fabry specialty care where amenable mutation status is known
• Patients seeking oral administration options after ERT discontinuation or poor infusion tolerance
• Treatment-naïve patients identified through newborn screening or early diagnosis pathways, once mutation amenability is confirmed

Why mutation testing matters for revenue

The size of the migalastat addressable market is constrained by the proportion of Fabry patients with GLA mutations categorized as “amenable.” Commercial outcomes track test volumes and test turnaround times because amenability confirmation is required for eligibility decisions.

How does GALAFOLD compete vs ERT and other Fabry therapies?

GALAFOLD competes in a segment where treatment choice is driven by:

• Route of administration (oral vs IV infusions)
• Patient adherence and tolerance profile
• Contracting and pharmacy benefit design
• Clinical outcomes tied to disease severity and baseline organ involvement

Key market dynamic: oral convenience can win payer coverage when specialty pharmacy economics and adherence data support lower total friction costs, but it does not eliminate competitive pressure when payers seek lowest-net-cost outcomes through bidding, switching rules, or tier placement.

What market dynamics drive GALAFOLD demand in the US and EU?

Demand is a function of (1) diagnosed patient pool growth, (2) the amenable mutation fraction, (3) specialty channel penetration, and (4) net price after rebates/discounts.

New diagnosis and treatment initiation cycles

Fabry diagnosis is influenced by:

• Family screening following an index diagnosis
• Expansion of genetic testing
• Clinical recognition in nephrology, cardiology, neurology, and dermatology

Treatment initiation cycles lag diagnosis because mutation confirmation and therapy selection workflows add time. That creates revenue timing effects even when diagnosed prevalence is stable.

Specialty pharmacy distribution and adherence economics

Migalastat is dispensed through specialty pharmacy channels. Commercial performance is therefore sensitive to:

• Prior authorization and step edits for oral migalastat
• Copay program participation and patient out-of-pocket limits
• Treatment persistence (missed doses reduce value perception and can drive discontinuation)

EU uptake patterns and payer behavior

In EU member states, uptake depends on:

• National rare disease treatment frameworks
• Centralized HTA or national HTA recommendations affecting formulary placement
• Budget impact concerns related to high-cost rare disease therapies

When does GALAFOLD face exclusivity and generic entry pressure?

The practical timing risk is driven by patent expirations and regulatory exclusivity periods that govern whether generic migalastat can be approved and marketed.

How to interpret exclusivity risk for a small-molecule rare disease drug

For an orally dosed small molecule like migalastat, generic approval can proceed once:

• Relevant drug product patents expire or are invalidated, and
• Any applicable regulatory exclusivity periods end, and
• FDA approval requirements for ANDA are met (including bioequivalence and labeling constraints)

If patents covering the active ingredient, compositions, or specific protected uses remain in force, a generic filer must navigate Paragraph IV or tailored design-around strategies.

What generic entry risks exist for GALAFOLD?

Generic entry risk is concentrated in:

• Years when composition-of-matter coverage on migalastat or core solid-form/composition claims expires
• Years when method-of-use or dose regimen claims tied to amenable mutation treatment expire
• Years when Orange Book-listed patents are no longer enforceable via terminal disclaimer or judicial outcomes

The scale of revenue erosion depends on launch timing relative to payer renegotiations and whether “no-interchange” policy exists for narrow eligibility therapies.

What patents protect GALAFOLD, and how strong is the patent estate?

The patent estate determines whether ANDA challengers can rely on carve-outs, label limitations, or design-around strategies.

Patent scope that matters commercially

For a rare disease oral drug, the most commercially protective patent categories are:

• Composition of matter covering migalastat itself
• Drug product formulation and solid-state forms (if any are Orange Book-listed)
• Methods of treatment that restrict administration to patients with specific genetic amenability criteria
• Dosing regimens tied to therapeutic effect

How patent strength affects financial trajectory

Strong estate coverage typically:

• Extends payer confidence in continued supply under branded pricing assumptions
• Delays generic launch and reduces switching pressure
• Increases settlement leverage in any Paragraph IV litigation

Weak estate coverage accelerates generic timelines, increases launch competition risk, and can trigger net price erosion through competitive tendering.

What is the Orange Book status of GALAFOLD?

Orange Book status is the gatekeeper for ANDA eligibility and is used by payers to understand switching likelihood. For GALAFOLD, the key indicators are:

• Number of listed patents
• Patent expiration dates (including any unexpired maintenance status)
• Whether patents include methods of use, compositions, or formulation claims
• Whether patents have been subject to litigation or agreed stipulations

Impact on financial trajectory: a dense Orange Book listing with long remaining life typically stabilizes pricing, while a reduced listing with imminent expirations accelerates payer-driven contract redesign and prepares tender alternatives.

What Paragraph IV challenges and GALAFOLD litigation affect market exclusivity?

Paragraph IV filings and subsequent litigation shape:

• Launch timing for generic migalastat
• Settlement terms that can include delayed launch dates
• Potential shared generic entry routes if patents are partially resolved

How litigation translates into revenue outcomes

• Early-stage litigation often delays launch, preserving branded share.
• Settlement can create a predictable generics timeline.
• Adverse decisions on key patents can force rapid contract repricing by payers, driving faster net price declines than a purely expiration-based scenario.

How does GALAFOLD compare with competitor Fabry therapies on market access and revenue risk?

GALAFOLD competes with ERTs and, depending on region, other systemic Fabry treatments.

ERT penetration and switching

ERTs have established prescriber familiarity and long payer track records. Switch to GALAFOLD generally depends on:

• Mutation amenability
• Patient preference and infusion burden
• Clinical outcomes and organ involvement
• Payer policies that treat oral therapies as preferred or restricted options

Oral convenience vs payer price sensitivity

Oral convenience helps with adherence and patient preference. It does not shield revenue if:

• Payers treat rare disease drugs through aggressive net pricing,
• Biosimilar-like competition exists in infusion supply chains (for ERT),
• Or contracting favors the lowest net-cost therapy for eligible patients.

What is the expected financial trajectory for GALAFOLD: revenue growth, pricing, and durability?

A financial trajectory for GALAFOLD usually tracks three measurable levers:

1. Volume growth from diagnosis and initiation rates of amenable patients
2. Net price driven by reimbursement rates, rebate structures, and payer contracting
3. Discontinuation and persistence influenced by tolerability and adherence patterns

Revenue growth drivers

• Expanding diagnosed Fabry population
• Increasing clinician adoption once amenable mutation testing becomes routine
• Patient switching from IV to oral where clinically appropriate and payer-approved

Revenue headwinds

• Mutation amenability classification limits addressable prevalence
• Formulary tightening and prior authorization intensity
• Net price pressure from contracting cycles and competitive tender dynamics

What to watch for earnings volatility

• Year-to-year testing volume shifts (amenable identification)
• Reimbursement contract renewals with major payers
• Specialty pharmacy channel changes that alter uptake friction
• Any unresolved patent litigation events affecting perceived exclusivity durability

Which companies are challenging GALAFOLD, and what are likely generic launch scenarios?

Generic challengers and settlement counterparties are typically identified by:

• Companies that filed ANDAs with Paragraph IV certifications
• Litigation case captions in federal court
• Public settlement agreements linked to delayed launches

Scenario map: brand revenue impact by entry path

• Delayed launch (settlement): branded revenue remains stable longer; net price erosion may still occur via payer anticipation but typically slower.
• Partial label carve-outs: generics can enter restricted indications, weakening brand share without full interchangeability.
• Full entry at patent expiry: steep share and price declines as payers switch to lowest-cost approved generic.

How does FDA and regulatory status affect GALAFOLD commercial runway?

FDA status drives US availability and determines labeling controls that influence payer coverage decisions.

Regulatory pathway relevance

For small molecules in rare diseases, regulatory milestones affect:

• Label expansions tied to additional amenable mutation sets (if any)
• Changes in prescribing criteria that broaden eligible patient population
• Postmarketing commitments influencing manufacturing continuity

Exclusivity and labeling constraints

Even with patent expiry, label constraints can slow uptake if payers require stricter criteria for substitution.

Key Takeaways

• GALAFOLD’s revenue trajectory is constrained by the amenable GLA mutation fraction, making mutation testing capacity and diagnosis expansion core commercial drivers.
• Market dynamics are dominated by payer contracting, specialty pharmacy adherence economics, and competition from established Fabry treatment alternatives.
• Financial durability depends on patent and Orange Book coverage length plus any Paragraph IV litigation and settlements that affect generic migalastat launch timelines.
• Generic launch risk is concentrated around expiration of the most commercially protective patent categories, especially those affecting product composition, formulation, or method-of-use eligibility tied to amenable mutations.
• In forecasting, track three levers: eligible patient volume growth, net pricing under payer re-contracting, and persistence/discontinuation in specialty care.

FAQs

1) What factors determine how many Fabry patients are eligible for GALAFOLD?
Amenability of GLA mutations to migalastat and confirmation through genetic testing, plus physician and payer criteria tied to the labeled population.

2) How does specialty pharmacy placement affect GALAFOLD net revenue?
Dispensing channel design, prior authorization friction, copay program economics, and persistence rates influence realized uptake and net reimbursement.

3) What are the biggest indicators that generic migalastat launch is near?
Orange Book patent expirations with remaining listed coverage, Paragraph IV litigation milestones, and settlement announcements that establish delayed launch dates.

4) Do payer formularies treat GALAFOLD as interchangeable with other Fabry therapies?
Usually not on a strict interchange basis, because eligibility is mutation-dependent and route of administration affects benefit design and coverage policies.

5) How do patent settlements typically change financial outcomes for branded migalastat?
Settlements can delay generic entry, reduce uncertainty, and still lead to net price renegotiations as payers anticipate future competition.

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-07-24).
2. FDA prescribing information for GALAFOLD (migalastat). U.S. Food and Drug Administration. (Accessed 2026-07-24).
3. FDA labels and review documents related to migalastat for Fabry disease. U.S. Food and Drug Administration. (Accessed 2026-07-24).

DrugChatter Q&A for GALAFOLD

What are the side effects of Galafold?